Biofrontera Reports Q3 2026 Revenue Growth Amidst Liquidity Concerns and NASDAQ Compliance Issues
Biofrontera (BFRI) reported third-quarter 2026 net product revenue of $9.1 million, a 29.8% increase year-over-year driven by higher Ameluz unit volumes and lamp sales. Despite the top-line growth and improved gross margins, the company faces significant financial headwinds, including a net loss of $6.4 million ($0.42 per share) and a decrease in cash reserves to $3.2 million. The company's financial position has triggered critical warnings; management expressed substantial doubt regarding Biofrontera's ability to continue as a going concern for the next 12 months due to liquidity constraints. Additionally, a stockholders' deficit of $200,000 means the company currently fails to meet NASDAQ minimum stockholders' equity requirements.
Tickers: $BFAGY.CNV
Topics: Ameluz Unit Volume Gross Margin Net Loss Revenue Growth
Read the full article at Motley Fool
Part of the story Biofrontera Reports Q3 2026 Revenue Growth Amidst Liquidity Concerns and NASDAQ Compliance Issues (3 articles)